FDA Authorizes New First-Line Therapies for HER2-Positive Gastric and Esophageal Cancers

The FDA has approved zanidatamab-hrii, combined with chemotherapy, and optionally tislelizumab-jsgr, as a first-line treatment for adults with HER2-positive, unresectable, locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. This decision introduces new initial treatment options for patients battling these aggressive cancers, potentially improving outcomes.